X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (61841) 61841
Publication (4304) 4304
Newsletter (557) 557
Book Review (499) 499
Book Chapter (266) 266
Magazine Article (145) 145
Conference Proceeding (81) 81
Book / eBook (67) 67
Dissertation (61) 61
Web Resource (28) 28
Newspaper Article (11) 11
Data Set (9) 9
Reference (5) 5
Paper (4) 4
Trade Publication Article (3) 3
Government Document (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (44399) 44399
index medicus (21765) 21765
male (20779) 20779
platelet aggregation inhibitors - therapeutic use (18168) 18168
female (17178) 17178
animals (15348) 15348
middle aged (12376) 12376
platelet aggregation - drug effects (11574) 11574
aggregation (11208) 11208
aged (10879) 10879
platelet aggregation inhibitors - pharmacology (9221) 9221
cardiac & cardiovascular systems (7837) 7837
ticlopidine - analogs & derivatives (7278) 7278
platelet aggregation inhibitors - administration & dosage (7274) 7274
aspirin (7128) 7128
adult (6943) 6943
treatment outcome (6905) 6905
aspirin - therapeutic use (6429) 6429
risk factors (6328) 6328
platelet aggregation inhibitors - adverse effects (6160) 6160
hematology (6036) 6036
peripheral vascular disease (6019) 6019
blood platelets - drug effects (5922) 5922
platelet aggregation (5820) 5820
pharmacology & pharmacy (5726) 5726
biochemistry & molecular biology (5604) 5604
clopidogrel (5566) 5566
time factors (4703) 4703
ticlopidine - therapeutic use (4516) 4516
blood platelets - metabolism (4302) 4302
rats (4202) 4202
drug therapy, combination (4066) 4066
thrombosis (3979) 3979
mice (3860) 3860
anticoagulants - therapeutic use (3793) 3793
dose-response relationship, drug (3658) 3658
analysis (3575) 3575
platelets (3522) 3522
blood platelets (3510) 3510
in vitro techniques (3347) 3347
aspirin - administration & dosage (3253) 3253
stents (3182) 3182
percutaneous coronary intervention (3163) 3163
aged, 80 and over (3143) 3143
medicine, general & internal (3106) 3106
inhibition (3035) 3035
proteins (3025) 3025
risk (2893) 2893
activation (2867) 2867
cell biology (2803) 2803
abridged index medicus (2801) 2801
stroke (2785) 2785
platelet-aggregation (2706) 2706
prospective studies (2706) 2706
prevention (2609) 2609
therapy (2571) 2571
research (2546) 2546
surgery (2536) 2536
myocardial-infarction (2535) 2535
disease (2454) 2454
care and treatment (2416) 2416
ticlopidine - administration & dosage (2399) 2399
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (2358) 2358
neurosciences (2345) 2345
acute coronary syndromes (2306) 2306
retrospective studies (2293) 2293
antiplatelet therapy (2290) 2290
aspirin - pharmacology (2282) 2282
drug therapy (2267) 2267
blood platelets - physiology (2264) 2264
mortality (2212) 2212
rabbits (2177) 2177
platelet aggregation inhibitors (2144) 2144
follow-up studies (2142) 2142
aspirin - adverse effects (2140) 2140
ticlopidine - adverse effects (2139) 2139
fibrinolytic agents - therapeutic use (2088) 2088
adenosine diphosphate - pharmacology (2072) 2072
anticoagulants (2057) 2057
hemorrhage - chemically induced (2017) 2017
risk assessment (1989) 1989
angioplasty, balloon, coronary (1988) 1988
cardiovascular (1945) 1945
myocardial infarction - drug therapy (1942) 1942
article (1941) 1941
in-vitro (1926) 1926
chemistry, medicinal (1907) 1907
thrombosis - prevention & control (1882) 1882
clinical neurology (1879) 1879
cardiology (1869) 1869
cells, cultured (1852) 1852
platelet activation - drug effects (1843) 1843
alzheimers-disease (1828) 1828
acute myocardial-infarction (1817) 1817
stroke - prevention & control (1807) 1807
kinetics (1783) 1783
randomized controlled trials as topic (1750) 1750
health aspects (1745) 1745
heart attacks (1725) 1725
protein aggregation (1691) 1691
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (34) 34
Online Resources - Online (28) 28
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
UofT at Mississauga - Stacks (4) 4
Chemistry (A D Allen) - Stacks (3) 3
UTL at Downsview - May be requested (3) 3
Engineering & Comp. Sci. - Stacks (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Mathematical Sciences - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
UofT at Scarborough - Stacks (1) 1
UofT at Scarborough - Withdrawn (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (58061) 58061
German (1012) 1012
French (733) 733
Japanese (599) 599
Russian (583) 583
Spanish (495) 495
Chinese (401) 401
Italian (281) 281
Polish (154) 154
Dutch (77) 77
Portuguese (67) 67
Danish (54) 54
Hungarian (48) 48
Swedish (46) 46
Czech (42) 42
Turkish (38) 38
Korean (35) 35
Norwegian (32) 32
Hebrew (21) 21
Ukrainian (17) 17
Finnish (15) 15
Serbian (14) 14
Croatian (9) 9
Lithuanian (9) 9
Romanian (9) 9
Slovak (8) 8
Icelandic (4) 4
Bosnian (2) 2
Bulgarian (1) 1
Latvian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9798, pp. 1231 - 1243
Summary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary... 
Internal Medicine | STROKE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | THERAPY | MYOCARDIAL-INFARCTION | AVAILABILITY | HEART-FAILURE | SELF-REPORT | ACUTE CORONARY SYNDROMES | MEDICINES | VALIDITY | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Data Collection | Secondary Prevention | Stroke - drug therapy | Urban Population | Antihypertensive Agents - therapeutic use | Drug Utilization | Cardiovascular Agents - therapeutic use | Developed Countries | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Rural Population | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Adult | Female | Aged | Developing Countries | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Care and treatment | Research | Cardiovascular diseases | Health aspects | Cardiovascular agents | Studies | Low income groups | Stroke | Households | Socioeconomic factors | Data collection | Cardiovascular disease | Epidemiology | Economic development | Community | Drug use | Antihypertensive Agents/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Cardiovascular Agents/therapeutic use | Coronary Disease/drug therapy | Cardiovascular Diseases/prevention & control | Platelet Aggregation Inhibitors/therapeutic use | Stroke/drug therapy | MEDICIN OCH HÄLSOVETENSKAP | Adrenergic beta-Antagonists/therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | MEDICAL AND HEALTH SCIENCES
Journal Article
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Diaz, Rafael and Widimsky, Peter and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Keltai, Katalin and Maggioni, Aldo P and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Pogosova, Nana and Ryden, Lars and Fox, Keith A A and Bhatt, Deepak L and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Avezum, Alvaro A and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 219 - 229
Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article
Chemical Society reviews, ISSN 0306-0012, 1/2017, Volume 46, Issue 2, pp. 31 - 323
Alzheimer's disease (AD) is characterized by an imbalance between production and clearance of amyloid-β (Aβ) species. Aβ peptides can transform structurally... 
Index Medicus | Oligomers | Inhibitors | Toxicity | Agglomeration | Alzheimer's disease | Monomers | Gain | Assembly
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 01/2015, Volume 22, Issue 3, pp. 373 - 404
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 09/2017, Volume 139, pp. 40 - 55
Many chronic human diseases, including multiple neurodegenerative diseases, are associated with deleterious protein aggregates, also called protein amyloids.... 
Covalent mechanisms | Non-covalent mechanisms | Amyloid inhibitor | Natural products | Inhibition mechanisms | CLINICAL-TRIAL | PROTEIN AGGREGATION | ALZHEIMERS-DISEASE | SOLID DISPERSION | TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE | ALPHA-SYNUCLEIN AGGREGATION | BETA-PEPTIDE AGGREGATION | A-BETA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | AROMATIC-INHIBITOR | Amyloidosis - prevention & control | Drugs, Investigational - pharmacology | Antioxidants - chemistry | Nootropic Agents - metabolism | Antioxidants - metabolism | Healthy Diet | Humans | Polyphenols - pharmacology | Drugs, Investigational - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Biological Products - pharmacology | Flavonoids - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Polyphenols - metabolism | Amyloidogenic Proteins - antagonists & inhibitors | Drugs, Investigational - chemistry | Protein Aggregation, Pathological - prevention & control | Amyloidosis - diet therapy | Drug Design | Flavonoids - pharmacology | Protein Aggregation, Pathological - diet therapy | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Chelating Agents - therapeutic use | Biological Products - therapeutic use | Chelating Agents - chemistry | Nootropic Agents - therapeutic use | Amyloidosis - drug therapy | Antioxidants - pharmacology | Chelating Agents - pharmacology | Nootropic Agents - chemistry | Drug Discovery | Protein Aggregation, Pathological - drug therapy | Amyloidogenic Proteins - metabolism | Antioxidants - therapeutic use | Biological Products - chemistry | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Flavonoids - metabolism | Polyphenols - chemistry | Biological Products - metabolism | Polyphenols - therapeutic use | Chelating Agents - metabolism | Dietary Supplements | Flavonoids - chemistry | Amyloidosis - metabolism | Nootropic Agents - pharmacology | Medicine, Experimental | Medical research | Nervous system diseases | Glycoproteins | Drug discovery | Index Medicus
Journal Article